October 14th, 2022 (Earnings Report)Dear Reader,Our scanners just identified several healthtech stocks that are expected to release earnings starting today, May 25th.If you are interested in any of these companies, we encourage you to do your own research and due diligence before pursuing any investments.Keep in mind, the actual earnings date and time may change, so if you’re interested in any of these companies you will need to pay close attention to their announcements.
Abbott Labs
Symbol: ABT
Recent Price: $100.91
Average Analyst Price Target: $123.08 (21.97%)
Market Cap: $179.45B
Last Year's EPS: $1.4
Consensus EPS Forecast: $0.95
Expected Earnings Date: Oct 18 2022
Recent Analyst Action: Matthew Taylor, analyst at Jefferies, reiterates coverage on Abbott Labs (ABT) in the Healthcare sector with a Hold rating and a price target of $ 110 (2 days ago).
TipRanks.com also reports that Abbott Labs currently has 14 analysts offering 12-month price targets and the consensus is a Moderate Buy rating with an average price target is $123.08 . The target pricing ranges from a high forecast of $140.00 down to a low forecast of $104.00. Abbott Labs (ABT)’s last closing price was $100.91 which would put the average price target at 21.97% upside.Here are 3rd party ratings for ABT:
- TipRanks.com: Moderate Buy
- TradingView.com: Sell
- Yahoo! Finance: Bullish Short-Term Outlook
- Barchart.com: Strong sell
- Zacks.com: Hold, Bottom 42% (146 out of 251)
--------------------------------------------------------------------------
Brainstorm Cell Therapeutics
Symbol: BCLI
Recent Price: $3.48
Average Analyst Price Target: $8.00 (129.89%)
Market Cap: $129.53M
Last Year's EPS: -$0.15
Consensus EPS Forecast: -$0.18
Expected Earnings Date: Oct 18 2022
Recent Analyst Action: Jason McCarthy, analyst at Maxim Group, reiterates coverage on Brainstorm Cell Therapeutics (BCLI) in the Healthcare sector with a Buy rating and a price target of $ 8 (4 weeks ago).
TipRanks.com also reports that Brainstorm Cell Therapeutics currently has 1 analysts offering 12-month price targets and the consensus is a Moderate Buy rating with an average price target is $8.00 . The target pricing ranges from a high forecast of $8.00 down to a low forecast of $8.00. Brainstorm Cell Therapeutics (BCLI)’s last closing price was $3.48 which would put the average price target at 129.89% upside.Here are 3rd party ratings for BCLI:
- TipRanks.com: Moderate Buy
- TradingView.com: Sell
- Yahoo! Finance: Bullish Short-Term Outlook
- Barchart.com: buy
- Zacks.com: n/a
--------------------------------------------------------------------------
Elevance Health
Symbol: ELV
Recent Price: $470.77
Average Analyst Price Target: $549.70 (16.77%)
Market Cap: $113.79B
Last Year's EPS: $6.79
Consensus EPS Forecast: $7.15
Expected Earnings Date: Oct 18 2022
Recent Analyst Action: Kevin Fischbeck, analyst at Bank of America Securities, reiterates coverage on Elevance Health (ELV) in the Healthcare sector with a Buy rating and a price target of $ 575 (1 month ago).
TipRanks.com also reports that Elevance Health currently has 10 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $549.70 . The target pricing ranges from a high forecast of $580.00 down to a low forecast of $485.00. Elevance Health (ELV)’s last closing price was $470.77 which would put the average price target at 16.77% upside.Here are 3rd party ratings for ELV:
- TipRanks.com: Strong Buy
- TradingView.com: Neutral
- Yahoo! Finance: Bullish Short-Term Outlook
- Barchart.com: sell
- Zacks.com: Sell, Bottom 46% (136 out of 251)
--------------------------------------------------------------------------
To Your Financial Future,
The Editor, HealthTechMovers.com
